1. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up;Aznab;Hematol. Oncol.,2017
2. Inhibition by methylated organo-arsenicals of the respiratory 2-oxo-acid dehydrogenases;Bergquist;J. Organomet Chem.,2009
3. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells;Chen;Cancer Res,2003
4. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells;Chen;Cancer Res,2003
5. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells;Chen;Cancer Res,2003